- Efficient synthesis of small-sized phosphonated dendrons: Potential organic coatings of iron oxide nanoparticles
-
We report herein the synthesis of biocompatible small-sized phosphonated monomers and dendrons used as functional coatings of metal oxide nanoparticles, more specifically superparamagnetic iron oxides (SPIOs) for magnetic resonance imaging (MRI) and therapy through hyperthermia. The molecules were engineered to modulate their size, their hydrophilic and/or biocompatible character (poly(amido)amine versus oligoethyleneglycol), the number of anchoring phosphonate groups (monophosphonate versus phosphonic tweezers) and the number of peripheral functional groups for further grafting of dyes or specific vectors. Such a library of hydrophilic phosphonic acids opens new possibilities for the investigation of dendronized nanohybrids as theranostics.
- Garofalo, Antonio,Parat, Audrey,Bordeianu, Catalina,Ghobril, Cynthia,Kueny-Stotz, Marie,Walter, Aurlie,Jouhannaud, Julien,Begin-Colin, Sylvie,Felder-Flesch, Delphine
-
supporting information
p. 5226 - 5239
(2014/12/10)
-
- NOVEL POLYBENZOFULVENE DERIVATIVES, SYNTHESIS AND USES THEREOF
-
The present invention relates to polymers of formula poly-3 (I), their synthesis, intermediates and uses thereof.
- -
-
Page/Page column 19
(2010/11/30)
-
- PROCESS FOR PREPARING NONAETHYLENE GLYCOL MONOMETHYL ETHER
-
The present invention provides a process for preparing nonethylene glycol monomethyl ether.
- -
-
Page/Page column 10-11
(2010/02/14)
-
- Novel alkanoic acid derivaties
-
There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R1 represents (CO)xC1-9alkyl or (CO)xC1-9fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R2 and R3 independently represent C1-3alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.
- -
-
-
- Calcitonin drug-oligomer conjugates, and uses thereof
-
Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.
- -
-
-
- Methods of treating periodontal disease
-
The present invention relates to novel compounds of formula (I): processes for their preparation, pharmaceutical formulations containing them, and their use in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, immune disorders, septic shock circulatory disorders, and gastrointestinal inflammation and disorders.
- -
-
-
- Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
-
A mixture of conjugates in which each conjugate in the mixture comprises a growth hormone drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed.
- -
-
-
- Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
-
A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may also result in less inter-subject variability than polydispersed mixtures of similar conjugates.
- -
-
-
- Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
-
A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. Moreover, the mixture may be more effective at surviving an in vitro model of intestinal digestion than non-conjugated calcitonin. Furthermore, the mixture may exhibit a higher bioavailability than non-conjugated calcitonin.
- -
-
-
- Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)phenyl derivatives, their preparation and their use in treatment of inflammatory conditions and immune disorders
-
The present invention provides a compound of formula (I) or a solvate thereof wherein: X is —O— or —NH—; Q is (—CH2—)p, (—CH═CH—)p, (—C≡C—)pwhere p is an integer of from 0 to 4; R1is hydrogen or methyl; R2and R3independently represent O or S n is an integer of 1 to 50; and R is hydrogen or methyl. The present invention also provides pharmaceutical compositions and methods of treatment using the compounds of formula (I). The compounds of the present invention are useful for the prophylaxis and treatment of septic shock, inflammatory conditions and immune disorders.
- -
-
Page column 14, 22
(2008/06/13)
-